KRAS and cancer: For example, in MTP19, KRAS p.G12V was present in the majority of IPMN samples, as well as all the invasive cancer samples, but there were an additional four other KRAS mutations (all occurring in hotspot positions) that were present in a small number of sections in low-grade IPMN samples (Fig. 3).